AFcell Medical, Inc., a designer and supplier of birth tissue forms under its AmnioClear brand, has hired David Buche as Chief Operating Officer. Buche comes to AFCell Medical with over 25 years experience in the biologics and medical device industry.
Most recently he was vice president for marking and product development instruments of Integra LifeSciences Corporation where he headed the $180 million division. Prior to joining Integra, Buche was vice president and chief operating officer of a 170 employee division of Synovis Life Technologies, Inc. During his 15 year tenure at Synovis, he led consistent growth by driving biological products to market and leading the commercialization of a new regenerative biological technology platform.
Before going to Synovis, Buche held sales and marketing positions for Spectranetics Corporation. He served in the U.S. Navy and earned degrees from the Carlson School of Business, University of Minnesota and California Coast University.
Robin Young, founder and CEO of AFcell Medical said, “David Buche’s extensive experience bringing biologic products to market and commercializing regenerative biologic technology platforms fits well with AFcell Medical’s culture of innovation for general surgery, wound care and orthopedic indications.”
Buche joins AFcell a few weeks after AFcell’s board of directors elected Olivier Carli its new chairman. Carli is the president of Denos, Ltd. and founder of Ideal Medical, one of the largest health care service companies in the world. Companies which Carli has founded or led have all become market leaders in more than 64 countries around the world.
